Key Points
- Berndt Modig, Pharvaris CEO, sold 2,292 shares on April 16 at an average price of $28.60 for about $65,551, leaving him with 139,792 shares (a 1.61% reduction valued at roughly $3.998M).
- He also sold 23,333 shares on April 9 at $27.74 for about $647,257, representing multiple recent insider sales.
- Pharvaris trades near $28.97 with a market cap of about $1.89B and recently missed quarterly EPS (-$0.84 vs. -$0.69 expected), yet analysts hold a "Moderate Buy" consensus with an average target of $42.73.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $28.60, for a total transaction of $65,551.20. Following the completion of the transaction, the chief executive officer directly owned 139,792 shares of the company's stock, valued at $3,998,051.20. This trade represents a 1.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Berndt Modig also recently made the following trade(s):
- On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total transaction of $647,257.42.
Pharvaris Stock Up 1.4%
NASDAQ:PHVS opened at $28.97 on Tuesday. The firm has a 50-day moving average price of $27.29 and a 200 day moving average price of $25.72. Pharvaris N.V. has a 12-month low of $13.81 and a 12-month high of $29.89. The firm has a market capitalization of $1.89 billion, a PE ratio of -8.60 and a beta of -2.58.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). On average, research analysts expect that Pharvaris N.V. will post -3.19 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Seven Fleet Capital Management LP bought a new position in Pharvaris in the 4th quarter valued at $1,536,000. XTX Topco Ltd lifted its position in Pharvaris by 126.1% during the 4th quarter. XTX Topco Ltd now owns 18,568 shares of the company's stock valued at $515,000 after purchasing an additional 10,355 shares during the period. Ikarian Capital LLC lifted its position in Pharvaris by 131.7% during the 4th quarter. Ikarian Capital LLC now owns 486,856 shares of the company's stock valued at $13,510,000 after purchasing an additional 276,691 shares during the period. Virtus Investment Advisers LLC lifted its position in Pharvaris by 66.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company's stock valued at $306,000 after purchasing an additional 4,407 shares during the period. Finally, SummitTX Capital L.P. acquired a new position in Pharvaris during the 4th quarter valued at about $634,000.
Analysts Set New Price Targets
PHVS has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Pharvaris in a research report on Thursday, April 9th. They issued an "outperform" rating and a $42.00 price target on the stock. Citigroup reiterated a "buy" rating on shares of Pharvaris in a research report on Wednesday, April 15th. Wall Street Zen downgraded Pharvaris from a "sell" rating to a "strong sell" rating in a research report on Monday, April 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Pharvaris in a research report on Thursday, January 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 price objective on shares of Pharvaris in a research report on Tuesday, March 3rd. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Pharvaris presently has an average rating of "Moderate Buy" and an average target price of $42.73.
Get Our Latest Stock Analysis on Pharvaris
Pharvaris Company Profile
(
Get Free Report)
Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.
The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
